Hypochloremic Alkalosis Workup

  • Author: Abbas AlAbbad, MD; Chief Editor: Bruce Buehler, MD   more...
 
Updated: Mar 30, 2012
 

Laboratory Studies

The following studies may be indicated in patients with hypochloremic alkalosis:

  • Amniocentesis
    • Amniotic fluid sodium and chloride concentrations may reflect fetal values; these are high in fetuses with chloride-losing diarrhea (CLD). Levels may also be elevated in patients with Bartter syndrome.
    • Although this study is not routine, α 1 -fetoprotein levels may be elevated.
  • Blood workup
    • Serum electrolyte levels may be within the reference range, especially in neonates and treated patients.
    • Typical findings include low concentrations of serum chloride, sodium, and potassium.
    • Serum pH and bicarbonate, calcium, uric acid, hemoglobin (if patient is not anemic), renin, and aldosterone levels may be elevated.
    • The serum rennin level is exponentially high in line with secondary hyperaldosteronism due to chronic volume depletion, and this finding is supported by low or normal blood pressure measurements.
    • Attention must be paid in interpreting the serum potassium level in relation to the state of metabolic alkalosis. For example, the potassium shift from serum into the intracellular compartment increases as the serum pH is high; in other words, the potassium level is less than normal by 0.6 mmol/L when measured at a serum pH of 7.5.
  • Urine and stool electrolytes
    • In patients with Bartter syndrome, urine chloride, sodium, and potassium concentrations are usually measured. Urine calcium-to-creatinine and uric acid–to–creatinine ratios are usually high. Stool electrolytes cannot be measured because of well-formed or hard stool. Fractional excretion (Fex) studies are more reliable than absolute values. Usually, results are higher than reference range values, as follows:
      • Fex sodium concentration greater than 1%
      • Fex potassium concentration greater than 35%
      • Fex chloride concentration greater than 2.5% (2.7% +/- 1.1%)
    • In patients with CLD, urine chloride concentration is very low or undetectable (< 10 mmol/L). Stool is usually watery, and electrolyte studies are very helpful and diagnostic, as follows:
      • Stool chloride concentration is greater than 100 mmol/L.
      • Stool sodium and potassium concentrations are elevated.
      • Stool chloride concentration is greater than stool sodium plus potassium concentrations, which is normally less than either. Chloride concentrations are lowest in colonic secretions and are usually less than 35 mmol/L.
      • Ratio of stool chloride to combined sodium and potassium concentrations is greater than 0.6.
    • Patients with cystic fibrosis typically demonstrate high sweat chloride and sodium concentrations. Urine chloride concentration is usually very low, and stools are usually not watery as they are in patients with CLD.
  • Renal function: Renal function is usually normal. Glomerular filtration rate (GFR) may be low in patients with severe disease.
  • Liver function tests: Liver function test results are usually within the reference range in patients with CLD and Bartter syndrome but may be deranged in patients with cystic fibrosis.
Next

Imaging Studies

  • Ultrasonography
    • Prenatal ultrasonography may be useful in the detection of minimal polyhydramnios and assessment of intestinal fluid content, which is increased in patients with CLD.
    • Postnatal ultrasonography may be useful in the evaluation of a fluid-filled bowel, which is characteristically increased in patients with CLD. Ultrasonography may also assist in the evaluation of renal echogenicity, nephrocalcinosis, medullary or diffuse calcinosis, and renal growth. See the image below. Severe nephrocalcinosis in a 2-year-old child withSevere nephrocalcinosis in a 2-year-old child with Bartter syndrome.
  • Wrist radiography: This may be performed to assess bone age in infants with growth failure. Wrist radiography may also help assess bone density and the presence of rickets.
  • Brain CT scanning: Brain CT scans are useful for evaluation of brain growth and calcifications.
  • Upper GI series: An upper GI series assists in detecting gastroesophageal reflux and pyloric stenosis, which are case-dependent conditions.[6]
  • Renal nuclear scanning: This may help assess renal function but is not useful in all patients.
  • Brain MRI: This is helpful in patients who present with seizures.
Previous
Next

Other Tests

  • Electroencephalography: This is helpful in patients who present with seizures.
  • Genetic studies
    • DNA diagnosis is available for most congenital disorders that cause hypochloremic metabolic alkalosis.
    • For CLD, the CLD (SLC26A3) locus is on band 7q22-q31.1.[7, 8]
    • Bartter syndrome is identified by NKCC2, ROMK, and CLCNKB;[9] Bartter syndrome with deafness is identified by BSND; and Bartter syndrome with autosomal dominant hypocalcemia is identified by CASR.
    • For cystic fibrosis, the CFTR locus is on band 7q31.2.
    • For Gitelman syndrome, the NCCT locus is on 16q.
Previous
Next

Procedures

Physiologic studies of renal tubules by performing maximal free water clearance during hypotonic saline diuresis is indicated.

  • Oral water at 20 mL/kg is administered over 30 minutes, followed by one-half isotonic sodium chloride solution 600 mL/m2/h for 2-3 hours. During this time, urine is collected in aliquots over 30-minute periods for 4-6 aliquots. These samples are sent for evaluation of creatinine, sodium, potassium, and chloride levels, and for osmolality, pH, and volume.
  • Usually, urine is diluted by administration of oral water.
  • Halfway through each collection, a blood sample is obtained for evaluation of creatinine, sodium, potassium, and chloride levels, and for pH and osmolality.
  • Calculate the clearance of each substance, then determine the ratio by dividing water clearance by the sum of chloride clearance and water clearance: (water clearance)/(chloride clearance + water clearance).
  • Usually, the results of the above equation reflect the percentage of distal tubule sodium and chloride reabsorption. Normal values are up to 85-90%, which means that the percentage of chloride and sodium excreted should be 10-15% (this is corrected to 100 mL GFR). In patients with Bartter syndrome, the percentage of chloride and sodium excreted can reach 35% or more.
Previous
Next

Histologic Findings

  • Renal biopsy is not usually indicated, but, if performed, it may reveal interstitial fibrosis and calcium/urate crystal deposition.
Previous
 
 
Contributor Information and Disclosures
Author

Abbas AlAbbad, MD  Consultant Pediatric Nephrologist, Section of Pediatric Nephrology, Department of Pediatrics, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia

Abbas AlAbbad, MD is a member of the following medical societies: American Academy of Pediatrics, International Pediatric Transplant Association, and International Society for Peritoneal Dialysis

Disclosure: Nothing to disclose.

Coauthor(s)

Robert J Ferry Jr, MD  Le Bonheur Chair of Excellence in Endocrinology, Professor and Chief, Division of Pediatric Endocrinology and Metabolism, Department of Pediatrics, University of Tennessee Health Science Center

Robert J Ferry Jr, MD is a member of the following medical societies: American Academy of Pediatrics, American Diabetes Association, American Medical Association, Endocrine Society, Pediatric Endocrine Society, Society for Pediatric Research, and Texas Pediatric Society

Disclosure: Eli Lilly & Co Grant/research funds Investigator; MacroGenics, Inc Grant/research funds Investigator; Ipsen, SA (formerly Tercica, Inc) Grant/research funds Investigator; NovoNordisk SA Grant/research funds Investigator; Diamyd Grant/research funds Investigator; Bristol-Myers-Squibb Grant/research funds Other; Amylin Other; Pfizer Grant/research funds Other; Takeda Grant/research funds Other

Specialty Editor Board

Christian J Renner, MD  Consulting Staff, Department of Pediatrics, University Hospital for Children and Adolescents, Erlangen, Germany

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Leonard G Feld, MD, PhD, MMM, FAAP  Sara H Bissell and Howard C Bissell Endowed Chair in Pediatrics, Chief Medical Officer, Levine Children's Hospital, Carolinas Medical Center

Leonard G Feld, MD, PhD, MMM, FAAP is a member of the following medical societies: American Academy of Pediatrics, American College of Physician Executives, American Society of Nephrology, American Society of Pediatric Nephrology, International Society of Nephrology, and Juvenile Diabetes Foundation International

Disclosure: Nothing to disclose.

Paul D Petry, DO, FACOP, FAAP  Consulting Staff, Freeman Pediatric Care, Freeman Health System

Paul D Petry, DO, FACOP, FAAP is a member of the following medical societies: American Academy of Osteopathy, American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association

Disclosure: Nothing to disclose.

Chief Editor

Bruce Buehler, MD  Professor, Department of Pediatrics and Genetics, Director RSA, University of Nebraska Medical Center

Bruce Buehler, MD is a member of the following medical societies: American Academy for Cerebral Palsy and Developmental Medicine, American Academy of Pediatrics, American Association on Mental Retardation, American College of Medical Genetics, American College of Physician Executives, American Medical Association, and Nebraska Medical Association

Disclosure: Nothing to disclose.

Additional Contributors

The author would like to thank Gloria Matthews (University of Texas Health Science Center at San Antonio Pediatrics) for her expert assistance with grants administration.

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Pinar Ozand, MD, PhD, to the development and writing of this article.

References
  1. Akil I, Ozen S, Kandiloglu AR, Ersoy B. A patient with Bartter syndrome accompanying severe growth hormone deficiency and focal segmental glomerulosclerosis. Clin Exp Nephrol. Jun 2010;14(3):278-82. [Medline].

  2. Al-Abbad A, Nazer H, Sanjad SA, Al-Sabban E. Congenital chloride diarrhea: A single center experience with ten patients. Ann Saudi Med. Sep 1995;15(5):466-9. [Medline].

  3. [Guideline] Grosse SD, Boyle CA, Botkin JR, et al. Newborn screening for cystic fibrosis: evaluation of benefits and risks and recommendations for state newborn screening programs. MMWR Recomm Rep. Oct 15 2004;53:1-36. [Medline].

  4. Aranzamendi RJ, Breitman F, Asciutto C, Delgado N, Castanos C. [Dehydration and metabolic alkalosis: an unusual presentation of cystic fibrosis in an infant]. Arch Argent Pediatr. Oct 2008;106(5):443-6. [Medline].

  5. Naesens M, Steels P, Verberckmoes R. Bartter's and Gitelman's syndromes: from gene to clinic. Nephron Physiol. 2004;96(3):p65-78. [Medline].

  6. Hulka F, Campbell TJ, Campbell JR, Harrison MW. Evolution in the recognition of infantile hypertrophic pyloric stenosis. Pediatrics. Aug 1997;100(2):E9. [Medline].

  7. Hoglund P, Haila S, Socha J, et al. Mutations of the Down-regulated in adenoma (DRA) gene cause congenital chloride diarrhoea. Nat Genet. Nov 1996;14(3):316-9. [Medline].

  8. Makela S, Kere J, Holmberg C. SLC26A3 mutations in congenital chloride diarrhea. Hum Mutat. Dec 2002;20(6):425-38. [Medline].

  9. Simon DB, Bindra RS, Mansfield TA, et al. Mutations in the chloride channel gene, CLCNKB, cause Bartter's syndrome type III. Nat Genet. Oct 1997;17(2):171-8. [Medline].

  10. Hanna JD, Scheinman JI, Chan JC. The kidney in acid-base balance. Pediatr Clin North Am. Dec 1995;42(6):1365-95. [Medline].

  11. Jacobson HR. Chloride-responsive metabolic alkalosis. In: Seldin DW, Gieb G, eds. The Regulation of Acid-Base Balance. Lippincott-Raven; 1989:431-57.

  12. Rose BD. Causes of metabolic alkalosis. UpToDate. Available at http://www.uptodate.com/.

  13. Rose BD. Treatment of metabolic alkalosis. UpToDate. Available at http://www.uptodate.com/.

  14. Rose BD. Urine electrolytes in diagnosis of metabolic alkalosis. UpToDate. Available at http://www.uptodate.com/.

  15. Simon DB, Karet FE, Hamdan JM, et al. Bartter's syndrome, hypokalaemic alkalosis with hypercalciuria, is caused by mutations in the Na-K-2Cl cotransporter NKCC2. Nat Genet. Jun 1996;13(2):183-8. [Medline].

  16. Wang J, Cortina G, Wu SV, et al. Mutant neurogenin-3 in congenital malabsorptive diarrhea. N Engl J Med. Jul 20 2006;355(3):270-80. [Medline].

Previous
Next
 
Infant with severe metabolic alkalosis resulting from congenital chloride-losing diarrhea.
Watery stool from an infant with congenital chloride-losing diarrhea. Chloride level was 205 mmol/L.
Renal ultrasonograph of an infant with congenital chloride-losing diarrhea showing diffuse sclerosis.
Severe nephrocalcinosis in a 2-year-old child with Bartter syndrome.
Visible bowel loops in an infant with congenital chloride-losing diarrhea.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.